Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TNYA | US
-0.11
-5.12%
Healthcare
Biotechnology
30/06/2024
18/10/2024
2.04
2.21
2.52
1.99
Tenaya Therapeutics Inc. a biotechnology company discovers develops and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration gene therapy and precision medicine platforms. The company is developing TN-201 a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301 a small molecule for heart failure with preserved ejection fraction; and TN-401 a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco California.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
127.7%1 month
102.3%3 months
89.2%6 months
83.1%-
-
1.27
0.12
0.10
-0.67
-
-
-118.31M
160.93M
160.93M
-
-
-
-
-74.54
12.39
9.23
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.91
Range1M
0.91
Range3M
2.45
Rel. volume
4.39
Price X volume
5.57M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Adverum Biotechnologies Inc | ADVM | Biotechnology | 8.48 | 176.39M | 4.95% | n/a | 43.97% |
Achieve Life Sciences Inc | ACHV | Biotechnology | 5.08 | 174.45M | 0.59% | n/a | 41.73% |
Acumen Pharmaceuticals Inc. Common Stock | ABOS | Biotechnology | 2.86 | 171.83M | 7.52% | n/a | 11.57% |
MOLECULAR PARTNERS AG | MOLN | Biotechnology | 4.87 | 161.65M | -2.21% | n/a | 1.96% |
LogicBio Therapeutics Inc | LOGC | Biotechnology | 6.07 | 159.49M | 1.17% | n/a | 0.00% |
Alpha Tau Medical Ltd. Class A Ordinary Shares | DRTS | Biotechnology | 2.25 | 157.33M | -2.17% | n/a | 16.97% |
BIOR | BIOR | Biotechnology | 4.3 | 156.82M | -22.35% | n/a | -52.57% |
Compugen Ltd | CGEN | Biotechnology | 1.71 | 153.11M | -1.16% | n/a | 5.19% |
Centrexion Therapeutics Corporation | CNTX | Biotechnology | 2.04 | 153.00M | 1.49% | n/a | 0.00% |
Repare Therapeutics Inc | RPTX | Biotechnology | 3.43 | 151.62M | 2.39% | n/a | 1.07% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.61 | 141.65M | -3.67% | n/a | 58.43% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 32.28 | 92.70M | 0.72% | 5.16 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.48 | 90.67M | 0.91% | 14.48 | 7.10% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.9 | 19.65M | 2.38% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.03 | 18.60M | 5.10% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.538 | 7.80M | -6.65% | 0.03 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2201 | 3.95M | 4.26% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.76M | 1.92% | n/a | 17.32% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -12.28% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.38 | 0 | 0.37% | 22.53 | 56.33% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.67 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 1.27 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 89.18 | 72.80 | Riskier |
Debt to Equity | 0.12 | -1.23 | Expensive |
Debt to Assets | 0.10 | 0.25 | Cheaper |
Market Cap | 160.93M | 3.66B | Emerging |